Precision Targeted Therapy of Ovarian Cancer

Overview

Journal J Control Release

Specialty Pharmacology

Date 2016 Nov 7

PMID 27746277

Citations 33

Authors

Justin Sapiezynski

Oleh Taratula

Lorna Rodriguez-Rodriguez

Tamara Minko

Affiliations

Soon will be listed here.

Abstract

The review is aimed at describing modern approaches to detection as well as precision and personalized treatment of ovarian cancer. Modern methods and future directions of nanotechnology-based targeted and personalized therapy are discussed.

Citing Articles

Targeting the FSH/FSHR axis in ovarian cancer: advanced treatment using nanotechnology and immunotherapy.

Feng F, Liu T, Hou X, Lin X, Zhou S, Tian Y Front Endocrinol (Lausanne). 2025; 15:1489767.

PMID: 39741875 PMC: 11685086. DOI: 10.3389/fendo.2024.1489767.

Beyond 2D cell cultures: how 3D models are changing the study of ovarian cancer and how to make the most of them.

Cortesi M, Warton K, Ford C PeerJ. 2024; 12:e17603.

PMID: 39221267 PMC: 11366228. DOI: 10.7717/peerj.17603.

Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells.

Romaniuk-Drapala A, Skupin-Mrugalska P, Garbuzenko O, Hatefi A, Minko T Cancer Cell Int. 2024; 24(1):285.

PMID: 39135053 PMC: 11320834. DOI: 10.1186/s12935-024-03469-0.

Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.

Garbuzenko O, Sapiezynski J, Girda E, Rodriguez-Rodriguez L, Minko T Small. 2024; 20(41):e2307462.

PMID: 38342698 PMC: 11316847. DOI: 10.1002/smll.202307462.

Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.

Cai D, Liu T, Fang J, Liu Y J Cancer Res Clin Oncol. 2023; 149(11):9151-9165.

PMID: 37178426 DOI: 10.1007/s00432-023-04831-x.

References

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

Gordon M, Matei D, Aghajanian C, Matulonis U, Brewer M, Fleming G . Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006; 24(26):4324-32. DOI: 10.1200/JCO.2005.05.4221. View

Chow L, Endersby R, Zhu X, Rankin S, Qu C, Zhang J . Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 2011; 19(3):305-16. PMC: 3060664. DOI: 10.1016/j.ccr.2011.01.039. View

Saad M, Garbuzenko O, Minko T . Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (Lond). 2008; 3(6):761-76. PMC: 2628713. DOI: 10.2217/17435889.3.6.761. View

Angelo M, Bendall S, Finck R, Hale M, Hitzman C, Borowsky A . Multiplexed ion beam imaging of human breast tumors. Nat Med. 2014; 20(4):436-42. PMC: 4110905. DOI: 10.1038/nm.3488. View

Eichbaum M, Mayer C, Eickhoff R, Bischofs E, Gebauer G, Fehm T . The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer. 2011; 11:453. PMC: 3224456. DOI: 10.1186/1471-2407-11-453. View

Shah V, Taratula O, Garbuzenko O, Taratula O, Rodriguez-Rodriguez L, Minko T . Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res. 2013; 19(22):6193-204. PMC: 3846837. DOI: 10.1158/1078-0432.CCR-13-1536. View

Vlahov I, Santhapuram H, Kleindl P, Howard S, Stanford K, Leamon C . Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg Med Chem Lett. 2006; 16(19):5093-6. DOI: 10.1016/j.bmcl.2006.07.030. View

Schultz N, Lopez E, Saleh-Gohari N, Helleday T . Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 2003; 31(17):4959-64. PMC: 212803. DOI: 10.1093/nar/gkg703. View

10.

Dietel M, Johrens K, Laffert M, Hummel M, Blaker H, Pfitzner B . A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther. 2015; 22(9):417-30. DOI: 10.1038/cgt.2015.39. View

11.

Ricciardelli C, Oehler M . Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas. 2009; 62(3):270-5. DOI: 10.1016/j.maturitas.2009.01.001. View

12.

Rosen D, Wang L, Atkinson J, Yu Y, Lu K, Diamandis E . Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005; 99(2):267-77. DOI: 10.1016/j.ygyno.2005.06.040. View

13.

Li C, Heidt D, Dalerba P, Burant C, Zhang L, Adsay V . Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67(3):1030-7. DOI: 10.1158/0008-5472.CAN-06-2030. View

14.

Dharap S, Qiu B, Williams G, Sinko P, Stein S, Minko T . Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release. 2003; 91(1-2):61-73. DOI: 10.1016/s0168-3659(03)00209-8. View

15.

Zhang H, Liu T, Zhang Z, Payne S, Zhang B, McDermott J . Integrated Proteogenomic Characterization of Human High-Grade Serous Ovarian Cancer. Cell. 2016; 166(3):755-765. PMC: 4967013. DOI: 10.1016/j.cell.2016.05.069. View

16.

Aerts J, Wynendaele W, Paridaens R, Christiaens M, Van Den Bogaert W, Van Oosterom A . A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood. Ann Oncol. 2001; 12(1):39-46. DOI: 10.1023/a:1008317512253. View

17.

Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M . Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997; 74(2):193-8. DOI: 10.1002/(sici)1097-0215(19970422)74:2<193::aid-ijc10>3.0.co;2-f. View

18.

Carmen M, Fuller A, Matulonis U, Horick N, Goodman A, Duska L . Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003; 91(3):596-602. DOI: 10.1016/j.ygyno.2003.08.021. View

19.

Dharap S, Minko T . Targeted proapoptotic LHRH-BH3 peptide. Pharm Res. 2003; 20(6):889-96. DOI: 10.1023/a:1023839319950. View

20.

Skates S, Xu F, Yu Y, Sjovall K, Einhorn N, Chang Y . Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995; 76(10 Suppl):2004-10. DOI: 10.1002/1097-0142(19951115)76:10+<2004::aid-cncr2820761317>3.0.co;2-g. View